Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241784 · ClinicalTrials.gov registry record · Phase 1
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03241784 is a Phase 1 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 3 participants.
The verdict
NCT03241784, a Phase 1 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
Interventions
- BIOLOGICAL Interleukin-2
- BIOLOGICAL Autologous T-regulatory lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05-16 |
| Est. Completion | 2018-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03241784
The ClinicalTrials.gov registry entry for NCT03241784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Interleukin-2 is the first listed.
NCT03241784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03241784 about?
NCT03241784 is a clinical study titled "Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis". Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
What is the current status of trial NCT03241784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-05-16. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT03241784?
The interventions under investigation include: Interleukin-2 (BIOLOGICAL), Autologous T-regulatory lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03241784?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.